Invitation: Sobi's Q2 2024 report

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. The presentation can be followed livehere  or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call. To participate in the conference call, please use the following dial-in details:Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries, please...

STOCKHOLM, 03/07/2024 (informazione.it - comunicati stampa - salute e benessere)

The presentation can be followed live here  or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:
Sweden : +46 8 5051 0031
United Kingdom : +44 207 107 06 13
United States : +1 631 570 56 13
For other countries, please find the details  here .

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe , North America , the Middle East , Asia and Australia . In 2023, revenue amounted to SEK 22.1 billion . Sobi's share (STOCKHOLM: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn .

For details on how to contact the Sobi Investor Relations Team, please click here . For Sobi Media contacts, click here .
Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/invitation--sobi-s-q2-2024-report,c3999285

The following files are available for download:

 

View original content: https://www.prnewswire.co.uk/news-releases/invitation-sobis-q2-2024-report-302188900.html